On October 30, 2019 CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reported that it will report Q3 2019 financial results after the market close on Tuesday, November 5, 2019 (Press release, Cytosorbents, OCT 30, 2019, View Source [SID1234550080]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CytoSorbents’ management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q3 2019 followed by a question and answer session.

Conference Call Details:
Date: Tuesday, November 5, 2019
Time: 4:45 PM Eastern
Participant Dial-In: 877-451-6152
Conference ID: 13695453
Live Presentation Webcast: View Source

It is recommended that participants dial in approximately 10 minutes prior to the start of the call. There will also be a simultaneous live webcast of the conference call that can be accessed through the following audio feed link: View Source

An archived recording of the conference call will be available under the Investor Relations section of the Company’s website at View Source